BeiGene Ltd.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC
- Conditions
- Interventions
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 94
- Registration Number
- NCT04948697
- Locations
- 🇨🇳
Chongqing University Three Gorges Hospital, Chongqing, Chongqing, China
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Taipei Veterans General Hospital, Taipei, Taiwan
Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 377
- Registration Number
- NCT04921358
- Locations
- 🇨🇳
Xinqiao Hospital Affiliated to the Army Medical University, Chongqing, Chongqing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇦🇺The Northern Hospital, Epping, Victoria, Australia
Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 64
- Registration Number
- NCT04883957
- Locations
- 🇨🇳
Peking University Peoples Hospital, Beijing, Beijing, China
🇨🇳Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang, Jiangxi, China
A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 63
- Registration Number
- NCT04866017
- Locations
- 🇺🇸
XCancer/Centeral Care Center, Bolivar, Missouri, United States
🇦🇺Southern Medical Day Care Centre, Wollongong, New South Wales, Australia
🇦🇺Townsville Hospital, Douglas, Queensland, Australia
A Study of BGB-11417 in Participants With Myeloid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 260
- Registration Number
- NCT04771130
- Locations
- 🇦🇺
Austin Health, Heidelberg, Victoria, Australia
🇦🇺The Alfred Hospital, Melbourne, Victoria, Australia
🇦🇺Fiona Stanley Hospital, Murdoch, Western Australia, Australia
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 662
- Registration Number
- NCT04746924
- Locations
- 🇺🇸
Virginia Cancer Specialists, Fairfax, Virginia, United States
🇺🇸Providence Medical Foundation St Jude Heritage Healthcare, Fullerton, California, United States
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
AdvanTIG-203: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-02-01
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 125
- Registration Number
- NCT04732494
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan
🇹🇭Phramongkutklao Hospital, Bangkok, Thailand
Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors
- First Posted Date
- 2021-01-20
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 84
- Registration Number
- NCT04716634
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷National Cancer Center (NCC), Goyang-si, Gyeonggi-do, Korea, Republic of
🇨🇳Shandong Cancer Hospital, Jinan, Shandong, China
AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 178
- Registration Number
- NCT04693234
- Locations
- 🇨🇳
Mackay Memorial Hospital, Taipei, Taiwan
🇧🇬Medical center nadezhda clinical eood, Sofia, Bulgaria
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Participants
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 25
- Registration Number
- NCT04669262
- Locations
- 🇦🇺
Q PHARM, Herston, Queensland, Australia